全文获取类型
收费全文 | 4028篇 |
免费 | 265篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 164篇 |
妇产科学 | 89篇 |
基础医学 | 409篇 |
口腔科学 | 131篇 |
临床医学 | 512篇 |
内科学 | 759篇 |
皮肤病学 | 134篇 |
神经病学 | 344篇 |
特种医学 | 436篇 |
外科学 | 481篇 |
综合类 | 88篇 |
一般理论 | 2篇 |
预防医学 | 290篇 |
眼科学 | 33篇 |
药学 | 197篇 |
中国医学 | 2篇 |
肿瘤学 | 218篇 |
出版年
2021年 | 55篇 |
2020年 | 33篇 |
2019年 | 64篇 |
2018年 | 63篇 |
2017年 | 50篇 |
2016年 | 56篇 |
2015年 | 60篇 |
2014年 | 74篇 |
2013年 | 94篇 |
2012年 | 173篇 |
2011年 | 163篇 |
2010年 | 131篇 |
2009年 | 132篇 |
2008年 | 174篇 |
2007年 | 162篇 |
2006年 | 174篇 |
2005年 | 169篇 |
2004年 | 140篇 |
2003年 | 150篇 |
2002年 | 139篇 |
2001年 | 134篇 |
2000年 | 158篇 |
1999年 | 93篇 |
1998年 | 81篇 |
1997年 | 88篇 |
1996年 | 72篇 |
1995年 | 65篇 |
1994年 | 75篇 |
1993年 | 78篇 |
1992年 | 68篇 |
1991年 | 69篇 |
1990年 | 64篇 |
1989年 | 84篇 |
1988年 | 85篇 |
1987年 | 79篇 |
1986年 | 69篇 |
1985年 | 76篇 |
1984年 | 45篇 |
1983年 | 50篇 |
1982年 | 31篇 |
1981年 | 38篇 |
1980年 | 31篇 |
1979年 | 28篇 |
1978年 | 35篇 |
1977年 | 32篇 |
1975年 | 32篇 |
1972年 | 23篇 |
1971年 | 24篇 |
1970年 | 23篇 |
1967年 | 24篇 |
排序方式: 共有4296条查询结果,搜索用时 15 毫秒
91.
Talmadge JE; Schneider M; Keller J; Ruscetti F; Longo D; Pennington R; Bowersox O; Tribble H 《Blood》1989,73(6):1458-1467
In a series of studies designed to extend our understanding of interleukin-2 (IL-2) and to study the effect of biologic response modifiers on bone marrow, we observed that administering recombinant human (rH) IL-2 to normal mice resulted in an increase in the frequency of colony-forming units-culture (CFU-C) in bone marrow. In addition, rH IL-2 was able to accelerate host recovery from cyclophosphamide (CTX)- or radiation-induced bone marrow depression and peripheral blood leukopenia. Not only can rH IL-2 accelerate, in a dose-dependent manner, the return of bone marrow, peripheral blood cellularity, and CFU-C frequency to normal levels following cytoreduction by CTX or irradiation, but it also significantly increases CFU-C frequency to greater than normal levels. Furthermore, rH IL-2 can significantly prolong survival of animals receiving a lethal dose of irradiation or CTX. Thus, multiple mechanisms are responsible for the synergistic therapeutic activity associated with rH IL-2 and CTX. rH IL-2 does not act only as an immunomodulatory agent in the presence or absence of suppressor T cells, but also accelerates host recovery from cytoreductive agents, resulting in decreased leukopenia and perhaps resistances to secondary infection. Thus, rH IL-2 plus chemotherapy may increase therapeutic activity against neoplastic disease, not only by adding immune stimulation to the direct antitumor effect of the drug but also by allowing delivery of higher, more effective doses of chemotherapy. 相似文献
92.
The risk of nursing home admission in three communities 总被引:3,自引:0,他引:3
Foley DJ Ostfeld AM Branch LG Wallace RB McGloin J Cornoni-Huntley JC 《Journal of aging and health》1992,4(2):155-173
Beginning in 1982, the 3-year incidence of nursing home admission was determined for community-dwelling residents aged 65 and over in East Boston, Massachusetts (4%); New Haven, Connecticut (9%); and Iowa and Washington Counties, Iowa (12%). A common methodology was used to collect baseline risk factor and follow-up data on nursing home admissions among persons in each community as part of the National Institute on Aging's Established Populations for Epidemiologic Studies of the Elderly. A multivariate logistic regression model of baseline risk factors that included the participant's age, race, sex, history of prior admission, ADL limitations, cognitive function, living arrangements, and level of income predicted 80% of the users in each community. 相似文献
93.
We have further characterized the biological activities, mechanism of action, and target cell populations of recombinant human and murine thrombopoietin (rhTPO and rmTPO) in in vitro human and murine model systems. Alone, hTPO or mTPO stimulated the maturation of immature murine megakaryoblasts as measured in a single cell assay. The combination of hTPO or mTPO and interleukin-6 (IL-6) resulted in a further increase in megakaryocyte differentiation in this system. Murine TPO stimulated mouse megakaryocyte progenitor development. Human megakaryocyte progenitor development was potentiated by hTPO alone and further augmented in the presence of the early-acting cytokines (IL-3) or kit ligand/stem cell factor (KL/SCF). To further define the mechanism of action of TPO, neutralization studies were performed with antisera to IL-3, granulocyte-macrophage colony-stimulating factor (GM- CSF), IL-1 beta, and IL-11. No diminution in TPO activity was observed in the presence of these antisera. Moreover, because adhesive interactions are known to modulate hematopoiesis, we studied whether hTPO might alter such interactions between human bone marrow (BM) megakaryocytes and human BM stromal fibroblasts. No changes were observed in either megakaryocyte expression of the surface molecules lymphocyte function-associated antigen-1, very late activation antigen- 4, or intercellular adhesion molecule-1 or the adhesion of megakaryocytes to stromal fibroblasts after treatment with the growth factor. Furthermore, no induction of secretion of the cytokines IL-1 alpha, IL-1 beta, GM-CSF, IL-6, granulocyte-CSF, tumor necrosis factor- alpha, transforming growth factor-beta 1, or transforming growth factor- beta 2 by primary human BM megakaryocytes was noted after treatment of the cells with hTPO. To address whether TPO affects very primitive hematopoietic progenitors, we studied the residual cells from the BMs of mice treated with high doses of 5-fluorouracil. Although no effect of mTPO alone was noted on the viability or replication of such primitive murine progenitor populations, the triple combination of IL-3 + KL/SCF + TPO stimulated growth of megakaryocyte progenitors. These results indicate that TPO is a highly lineage-specific growth factor whose primary biological effects are likely to be direct modulation of the growth and maturation of committed megakaryocyte precursors and immature megakaryoblasts. 相似文献
94.
95.
96.
97.
98.
Cardiac disease in diabetic end-stage renal disease 总被引:2,自引:0,他引:2
R. N. Foley B. F. Culleton P. S. Parfrey J. D. Harriett G. M. Kent D. C. Murray Paul E. Barre 《Diabetologia》1997,40(11):1307-1312
Summary Little is known about the epidemiology of cardiac disease in diabetic end-stage renal disease. We therefore prospectively
followed a cohort of 433 patients who survived 6 months after the inception of dialysis therapy for an average of 41 months.
Clinical and echocardiographic data were collected yearly. At baseline, diabetic patients (n = 116) had more echocardiographic concentric left ventricular hypertrophy (50 vs 38 %, p = 0.04), clinically diagnosed ischaemic heart disease (32 vs 18 %, p = 0.003) and cardiac failure (48 vs 24 %, p < 0.00 001) than non-diabetic patients (n = 317). After adjusting for age and sex, diabetic patients had similar rates of progression of echocardiographic disorders,
and de novo cardiac failure, but higher rates of de novo clinically diagnosed ischaemic heart disease (RR 3.2, p = 0.0002), overall mortality (RR 2.3, p < 0.0001) and cardiovascular mortality (RR 2.6, p < 0.0001) than non-diabetic patients. Mortality was higher in diabetic patients following admission for clinically diagnosed
ischaemic heart disease (RR 1.7, p = 0.05) and cardiac failure (RR 2.2, p = 0.0003). Among diabetic patients older age, left ventricular hypertrophy, smoking, clinically diagnosed ischaemic heart
disease, cardiac failure and hypoalbuminaemia were independently associated with mortality. The excessive cardiac morbidity
and mortality of diabetic patients seem to be mediated via ischaemic disease, rather than progression of cardiomyopathy while
on dialysis therapy. Potentially remediable risk factors include smoking, left ventricular hypertrophy, and hypoalbuminaemia.
[Diabetologia (1997) 40: 1307–1312]
Received: 25 March 1997 and in final revised form: 23 June 1997 相似文献
99.
100.
Costa MA Sabate M Kay IP de Feyter PJ Kozuma K Serrano P de Valk V Albertal M Ligthart JM Disco C Foley DP Serruys PW 《The American journal of cardiology》2000,85(2):135-139
Currently, several different designs of coronary stents are available. However, only a few of the new generation stents have been investigated in large randomized trials. Mechanical behavior of first-generation stents (Palmaz-Schatz, Gianturco-Roubin) may not be applied to the new designs. We investigated the chronic mechanical behavior (recoil) of 2 stents recently approved by the Food and Drug Administration (MULTILINK and NIR). Forty-eight patients with single-stent implantation (23 MULTILINK and 25 NIR) were assessed by means of volumetric 3-dimensional intravascular ultrasound analysis after the procedure and at 6-month follow-up. In addition, volumetric assessment of neointimal formation was performed. No significant chronic stent recoil was detected in both groups (delta MULTILINK stent volume: +5.6+/-41 mm3 [p = NS] and delta NIR stent volume + 2.1+/-26 mm3 [p = NS]). A similar degree of neointimal formation at 6 months was observed between the 2 stents (MULTILINK 46+/-31.9 mm3 vs NIR 39.9+/-27.6 mm3, p = NS). In conclusion, these 2 second-generation tubular stents did not show chronic recoil and appeared to promote similar proliferative response after implantation in human coronary arteries. 相似文献